Vicenin 3
Based on 1 Customer Validation
Vicenin 3 is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 46.91 μM) that can be isolated from the aerial parts of Desmodium styracifolium. Vicenin 3 ameliorates IL-1β-induced extracellular matrix degradation in SW1353 chondrocytes by regulating the MAPK pathway. Vicenin 3 can be used for the study of osteoarthritis (OA) and hypertension.
For research use only. We do not sell to patients.
- Purity : 99.90%
- CAS No.: 59914-91-9
- Formula: C26H28O14
- Molecular Weight:564.49
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N2165
Vicenin 2ACE Inhibitor -
HY-B0331A
Enalapril maleateAngiotensin-Converting Enzyme Inhibitor -
HY-B0331AR
Enalapril maleate (Standard)Reference Standard -
HY-B0368
CaptoprilACE Inhibitor -
HY-B0331
EnalaprilAngiotensin-Converting Enzyme Inhibitor -
HY-A0043A
Cilazapril monohydrateACE Inhibitor -
HY-B0368R
Captopril (Standard)ACE Inhibitor -
HY-N4090R
Vicenin 3 (Standard)ACE Inhibitor -
HY-B0093A
Benazepril hydrochlorideACE Inhibitor -
HY-12404
Diminazene aceturateTrypanocidal Agent -
HY-19414
MLN-4760ACE2 Inhibitor -
HY-A0115
RamiprilatACE Inhibitor
Biological Activity
Description
In Vitro
Vicenin 3 (5-20 μM, pretreated for 1 h) significantly inhibits IL-1β-induced production of NO and PGE2 in SW1353 chondrocytes[1].
Vicenin 3 (5-20 μM, pretreated for 1 h) reverses IL-1β-induced increments in the levels of MMP-1, MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5, as well as the degradation of collagen type II and aggrecan in SW1353 chondrocytes[1].
Vicenin 3 (5-20 μM, pretreated for 1 h) ameliorates the degradation of ECM in IL‑1β‑treated SW1353 chondrocytes by blocking the p38 signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:IL-1β-induced SW1353 chondrocytes
-
Concentration:5, 20 μM
-
Incubation Time:pretreated for 1 h
-
Result:Inhibited IL-1β-induced production of NO and PGE2 in SW1353 chondrocytes.
Inhibited the levels of MMP-1, MMP-3, MMP-13.
-
Cell Line:IL-1β-induced SW1353 chondrocytes
-
Concentration:5, 20 μM
-
Incubation Time:pretreated for 1 h
-
Result:Inhibited the mRNA levels of MMP-1, MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5.
-
Cell Line:IL-1β-induced SW1353 chondrocytes
-
Concentration:5, 20 μM
-
Incubation Time:pretreated for 1 h
-
Result:Suppressed IL-1β-stimulated MAPK (ERK, JNK, p38) activation in SW1353 chondrocytes.
Blocked p38 activation.
Chemical Information
-
CAS No. 59914-91-9
-
Appearance Solid
-
Molecular Weight 564.49
-
Formula C26H28O14
-
Color Light yellow to green yellow
-
SMILES
OC1=C([C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)C(O)=C(C(C=C(C3=CC=C(O)C=C3)O4)=O)C4=C1[C@H]5[C@@H]([C@H]([C@H](O)CO5)O)O
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (177.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Invadopodia/Fluorescent Gelatin Degradation Assay
Invadopodia/fluorescent gelatin degradation assay detects proteolytic extracellular matrix degradation by cancer-cell invadopodia, which are actin-rich protrusive structures associated with matrix remodeling, invasion, and metastasis. The readout is generated by culturing cells on fluorescent gelatin and measuring dark degraded areas where fluorescent substrate has been locally removed, often together with immunofluorescent detection of invadopodia markers such as F-actin, cortactin, and TKS5.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ECM-Embedded Organoid (Matrigel/Dome) Culture
ECM-embedded organoid dome culture embeds epithelial stem cells, crypts, organoid fragments, or tumor-derived epithelial cells in a basement-membrane-like hydrogel such as Matrigel, allowing 3D growth, self-organization, lumen formation, budding or cystic morphogenesis, and lineage maintenance under defined niche-factor-containing medium. The primary readouts are organoid establishment efficiency, growth, morphology, passaging capacity, lineage-marker expression, and, when fluorescently labeled lines are used, microscopy- or flow-cytometry-based quantification of population behavior in 3D culture.
-
Matrigel/ECM Transwell Invasion Assay
The Matrigel/ECM Transwell invasion assay measures the ability of cells to move toward a chemoattractant while crossing an extracellular-matrix barrier placed on a porous membrane; therefore, the readout reflects both chemotactic motility and matrix invasion rather than migration alone. Matrigel is a basement-membrane-rich matrix derived from Engelbreth-Holm-Swarm mouse sarcoma and has been used as a reconstituted basement membrane barrier in chemoinvasion assays. The assay readout is generated by quantifying cells that reach the underside of the insert membrane or lower compartment after incubation, commonly by staining and counting invaded cells or by fluorescence-based quantification.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
-
Matrigel Transwell/Boyden Chamber Invasion Assay
Matrigel Transwell/Boyden chamber invasion assay measures the ability of cells to degrade or traverse an extracellular matrix-coated porous membrane and move from an upper chamber toward a chemoattractant in a lower chamber. Invasion is distinguished from migration by coating the membrane with Matrigel or basement membrane matrix; uncoated inserts measure migration, while coated inserts require cells to cross an ECM barrier before reaching the underside of the membrane.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen YY, et al. Vicenin 3 ameliorates ECM degradation by regulating the MAPK pathway in SW1353 chondrocytes. Exp Ther Med. 2021 Dec;22(6):1461. [Content Brief]
[2]. Zhang YQ, et al. Bioassay-guided preparative separation of angiotensin-converting enzyme inhibitory C-flavone glycosides from Desmodium styracifolium by recycling complexation high-speed counter-current chromatography. J Pharm Biomed Anal. 2015 Jan;102:276-81. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7715 mL | 8.8576 mL | 17.7151 mL | 44.2878 mL |
| 5 mM | 0.3543 mL | 1.7715 mL | 3.5430 mL | 8.8576 mL | |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7715 mL | 4.4288 mL | |
| 15 mM | 0.1181 mL | 0.5905 mL | 1.1810 mL | 2.9525 mL | |
| 20 mM | 0.0886 mL | 0.4429 mL | 0.8858 mL | 2.2144 mL | |
| 25 mM | 0.0709 mL | 0.3543 mL | 0.7086 mL | 1.7715 mL | |
| 30 mM | 0.0591 mL | 0.2953 mL | 0.5905 mL | 1.4763 mL | |
| 40 mM | 0.0443 mL | 0.2214 mL | 0.4429 mL | 1.1072 mL | |
| 50 mM | 0.0354 mL | 0.1772 mL | 0.3543 mL | 0.8858 mL | |
| 60 mM | 0.0295 mL | 0.1476 mL | 0.2953 mL | 0.7381 mL | |
| 80 mM | 0.0221 mL | 0.1107 mL | 0.2214 mL | 0.5536 mL | |
| 100 mM | 0.0177 mL | 0.0886 mL | 0.1772 mL | 0.4429 mL |
Vicenin 3 Related Classifications
HY-N4090 Related Classifications
Powered by Bioz